0.83
-0.0181(-2.12%)
Currency In USD
Address
1850 Gateway Drive
San Mateo, CA 94404
United States of America
Phone
650 216 3500
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
13
First IPO Date
February 11, 2011
| Name | Title | Pay | Year Born |
| Mr. Vincent J. Angotti | Chief Executive Officer & Director | 682,549 | 1968 |
| Mr. Anil N. Dasu | Chief Engineering Officer | 486,848 | 1963 |
| Mr. Raffi Mark Asadorian | Chief Financial Officer | 600,494 | 1969 |
| Dr. Shakil Aslam M.D. | Chief Medical Officer | 0 | 1965 |
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.